Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Estradiol for Vaginal Atrophy in Women with HIV
NCT04079218Phase 4Completed
- Start
- Sep 2020
- Primary completion
- Aug 2023
- Modality
- Hormone, Biologic
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of estradiol in vaginal atrophy (2 arms). Primary endpoints: Change in Most Bothersome Symptom (MBS) of Vaginal Atrophy at 12 weeks, Vaginal Microbiome - Relative Abundance of Lactobacillus Crispatus at 12 weeks and 1 more. Started Sep 2020; status: completed.
02
Drugs
estradiol
03
Conditions
vaginal atrophy
Beyond the preview
Go deeper on NCT04079218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04079218.